Elizabeth F. Redente, PhD, is a Professor in the Division of Cell Biology at National Jewish Health. She received her PhD in Molecular Toxicology from the University of Colorado School of Pharmacy. She holds joint appointments in the School of Pharmacy and in the Division of Pulmonary, Allergy and Critical Care Medicine in the School of Medicine at the University of Colorado. Her research centers on the development and resolution of pulmonary fibrosis, examining the roles of fibroblasts, macrophages, BCL-2 family members in fibroblast persistence, collagen degradation via matrix metalloproteinases such as MMP-9, macrophage lipid handling, and Muc5B mis-expression in epithelial-fibroblast communication. Dr. Redente leads the Redente Research Laboratory, utilizing genetic mouse models and clinical samples to advance understanding of these processes and identify therapeutic targets.
She serves as Science Leader for the Office of Research Innovation at National Jewish Health and as Chair of the Research Advisory Committee. Dr. Redente is actively involved in the American Thoracic Society, currently serving as Chair of the Respiratory Cell and Molecular Biology Assembly, and holds the designation ATSF. In 2019, she was awarded the Jo Rae Wright Award for Outstanding Achievement by a Young Investigator by the American Thoracic Society. Recent publications from her laboratory include work on nintedanib and BCL-2 in fibrotic fibroblasts published in the American Journal of Respiratory Cell and Molecular Biology in 2026 and conditional BCL-2 expression promoting persistent pulmonary fibrosis published in Nature Communications in 2026. Her contributions support training of graduate students, pulmonary fellows, and postdoctoral fellows in an inclusive research environment.